Amgen (AMGN) Reports Phase 3 CodeBreaK 200 trial of Lumakras Met Primary Endpoint
Go back to Amgen (AMGN) Reports Phase 3 CodeBreaK 200 trial of Lumakras Met Primary Endpoint| Amgen Inc (NASDAQ: AMGN) | Delayed: 404.21 +11.05 (2.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $393.16 | 52 Week High | $176.85 | |||
| Open | $405.25 | 52 Week Low | $133.64 | |||
| Day High | $407.00 | P/E | 60.88 | |||
| Day Low | $398.52 | EPS | $6.64 | |||
| Volume | 1,113,165 | |||||
